Checkpoint inhibitors have revolutionized cancer treatment, but they aren’t perfect, and there is a niche for therapies to treat those whose disease progresses despite receiving these therapies. Replimune Group Inc. believes its cancer vaccine RP1 (vusolimogene oderparepvec) could become the go-to option for melanoma patients in this situation following an impressive update from the IGNYTE trial.
ESMO 24: Replimune’s Cancer Vaccine Succeeds In PD-1 Failures
New data suggest that RP1 could become the therapy of choice in melanoma patients who do not respond to checkpoint inhibitors.
